drugset / Trial / NCT01235897
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
Phase 1
Completed
17 enrolled
University of California, San Francisco
Merck Sharp & Dohme LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and safest highest dose of an investigational drug called MK-2206 when given in combination with paclitaxel and trastuzumab in patients with Human Epidermal growth factor Receptor 2 (HER2)-overexpressing solid tumor malignancies.
Timeline
- Start
- 2011-03
- Primary completion
- 2013-03
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-2206 | Small molecule | 135 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Background | Trastuzumab | Monoclonal antibody | 2 mg/kg | — |